Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Investment Income (2016 - 2018)

Historic Investment Income for Silo Pharma (SILO) over the last 5 years, with Q2 2018 value amounting to -$239824.0.

  • Silo Pharma's Investment Income fell 474884.76% to -$239824.0 in Q2 2018 from the same period last year, while for Jun 2018 it was -$138699.0, marking a year-over-year decrease of 10646.21%. This contributed to the annual value of $826924.0 for FY2017, which is 2570.14% down from last year.
  • As of Q2 2018, Silo Pharma's Investment Income stood at -$239824.0, which was down 474884.76% from $152396.0 recorded in Q1 2018.
  • Silo Pharma's 5-year Investment Income high stood at $1.8 million for Q4 2016, and its period low was -$427488.0 during Q3 2017.
  • Its 5-year average for Investment Income is $103468.9, with a median of -$2473.0 in 2015.
  • Within the past 5 years, the most significant YoY rise in Silo Pharma's Investment Income was 101309.29% (2016), while the steepest drop was 349663990000.0% (2016).
  • Quarter analysis of 5 years shows Silo Pharma's Investment Income stood at -$401343.0 in 2014, then soared by 52.08% to -$192326.0 in 2015, then skyrocketed by 1013.09% to $1.8 million in 2016, then tumbled by 78.58% to $376217.0 in 2017, then crashed by 163.75% to -$239824.0 in 2018.
  • Its Investment Income stands at -$239824.0 for Q2 2018, versus $152396.0 for Q1 2018 and $376217.0 for Q4 2017.